The drugs are indicated for adults with locally advanced or metastatic non-small cell lung cancer with select mutations. They are the nation’s “first and only multitargeted, chemotherapy-free combination regimen with demonstrated superiority versus osimertinib” approved for this patient population, J&J said.
Osimertinib is approved to treat non-small cell lung cancer with these mutations.
The five-year survival rate is less than 20% for patients treated with monotherapy, according to J&J. A phase 3 trial showed that Rybrevant and Lazcluze reduced the risk of disease progression or death by 30% compared to osimertinib.
